Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) shares rose on Tuesday as the firm delivered new data on its lead drug, iclaprim, at the European Congress of Clinical Microbiology and Infectious Diseases, in Amsterdam.
The presentation provided a drill-down into the results from the company’s REVIVE Phase III study of people with skin and skin structure infections.
READ: Motif Bio receives vote of confidence as it raises £2.7mln
Among the headlines was an analysis by lesion size, which showed the antibiotic had comparable efficacy to vancomycin, the current standard of care.
Delegates heard the bacteremia rates were comparable between the two drugs, while the pharmacokinetics of iclaprim (the way the drug moves around the body) supported the use of a fixed dosing regimen.
Finally, Motif provided details of a recent lab-based data supporting iclaprim’s activity against Gram-positive bacteria collected from patients.
“Data are being presented that show that iclaprim continues to be active against a variety of antibiotic-resistant pathogens like methicillin-resistant (MRSA), methicillin-susceptible (MSSA) Staphylococcus aureus, and other Gram-positive skin and soft structure pathogens collected during 2017 from Europe and the US,” Motif said.
In early afternoon trading in London, Motif Bio shares were 4.9% higher at 8.82p.
-- Adds share price --
